This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NextGen (NXGN) Q1 Earnings Lag Estimates, Revenues Down Y/Y
by Zacks Equity Research
NextGen (NXGN) slashes guidance for fiscal 2020 owing to a dismal Q1.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
Varian (VAR) expects revenue growth in the range of 9-10% for fiscal 2019.
Cerner (CERN) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) Q2 results benefit from higher revenues, gains in Licensed software, Professional and Managed services units, and gross margin expansion.
Thermo Fisher (TMO) Beats on Q2 Earnings, Lifts Guidance
by Zacks Equity Research
Banking on a strong operational performance, Thermo Fisher (TMO) raises its 2019 revenue and earnings guidance.
Neogen's (NEOG) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Neogen's (NEOG) strong international business and solid performance by core Food Safety segment resulted in year-over-year revenue growth.
Boston Scientific (BSX) Q2 Earnings Top on Growth in All Lines
by Zacks Equity Research
Boston Scientific's (BSX) revenue strength across all business lines and geographies raises investors' optimism on the stock.
Medidata (MDSO) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Medidata (MDSO) gains from solid segmental contributions in Q2.
Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View
by Zacks Equity Research
Edwards Lifesciences (EW) Q2 results benefit from higher revenues, strong segmental performance and gross margin expansion.
Quest Diagnostics (DGX) Q2 Earnings, Revenues Beat Estimates
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access which has helped accelerate volume growth in the second quarter.
Abbott (ABT) Tops Q2 Earnings Estimates, Lifts EPS Guidance
by Zacks Equity Research
Abbott (ABT) registers strong Cardiovascular and Neuromodulation sales on double-digit growth in Electrophysiology, Heart Failure and Structural Heart.
Henry Schein Closes Acquisition of Elite Computer Italia
by Zacks Equity Research
The Elite Computer acquisition marks Henry Schein's (HSIC) foray into the Italian dental practice management software market.
Chemed's Roto-Rooter & VITAS Robust, Acuity Mix Shift Weak
by Zacks Equity Research
Chemed's (CHE) VITAS shows higher adoption via an expanded average daily census. Also, the Roto-Rooter's business grows on the back of strong core plumbing and drain cleaning service segments.
Masimo (MASI) Hits a 52-Week High on Solid Growth Drivers
by Zacks Equity Research
Masimo (MASI) gains from expansion of product portfolio and recent regulatory approvals.
Abbott MitraClip G4 Gets FDA Nod, Valve Repair Options Expand
by Zacks Equity Research
The FDA approval for MitraClip G4 is expected to enhance Abbott's (ABT) cardiac treatment portfolio.
Here's Why You Should Hold Onto Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors' trust continues to be high in Neogen (NEO), thanks to strength in its Food Safety and Genomic businesses.
TFX or STE: Which is a Better Investment Pick Right Now?
by Zacks Equity Research
STERIS (STE) scores higher than Teleflex (TFX) when it comes to valuation and one-year price performance.
Illumina (ILMN) Grows on Innovation & International Growth
by Zacks Equity Research
Illumina (ILMN) is benefiting from sturdy demand for sequencing and array systems as well as consumables and services.
NuVasive (NUVA) Launches Pulse Integrated Technology Platform
by Zacks Equity Research
The launch of this system is in sync with NuVasive's (NUVA) endeavor to deliver end-to-end solutions that offer predictable clinical and economic outcomes in spine surgery.
Boston Scientific's Global Growth Robust Amid Currency Woe
by Zacks Equity Research
Boston Scientific (BSX) is currently pinning hopes on a stronger performance in China, backed by the recent approval of SYNERGY in the country.
Medtronic Releases Positive Results of LATERAL Clinical Trial
by Zacks Equity Research
Positive outcomes prove to be a major breakthrough for Medtronic (MDT) in the growing field of ventricular assist devices.
ResMed (RMD) Rides on Strong SaaS Growth & New Product Suite
by Zacks Equity Research
ResMed's (RMD) new product menu and an array of strategies are likely to benefit from the sleep-disordered breathing market. This should further drive its short-term performance.
Integra Partners AI-Driven Data Analytics Firm in Wound Care
by Zacks Equity Research
Integra LifeSciences (IART) expects its partnership with Tissue Analytics to be perfectly strategic as the latter's software solutions automatically derive high quality data from clinical pictures.
Phibro Animal Sees Crucial Progress in ASF Vaccine Development
by Zacks Equity Research
The identification of a group of peptides and proteins is a remarkable step toward Phibro's (PAHC) development of a solution for ASF.
Fresenius Set for Global Expansion of Research Activities
by Zacks Equity Research
Fresenius Medical Care (FMS) aims to expand the scope of its clinical research activities through an integration move.
Illumina (ILMN) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Illumina (ILMN) gains from expansion of its product portfolio and strategic partnership.